Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must have met ACR criteria for the diagnosis of rheumatoid arthritis (RA)
Must have active RA
Must be treated with Methotrexate (MTX) (10 to 25 mg weekly) for at least 3 months and have received a stable dose for at least 28 days prior to the anticipated study drug administration date.
All other DMARDs or biologics must be discontinued at least 28 days prior to study drug administration and: 1) Leflunomide, which must be discontinued at least 60 days before study drug administration, 2) infliximab, adalimumab, and abatacept must be discontinued at least 56 days prior to study drug administration
You may not be if
Both Rheumatoid factor and anti-CCP negative
Prior treatment with any B-cell depleting therapy
Any other mAb or Ig-based fusion proteins 56 days or less prior to Visit
History of or current inflammatory joint disease other than RA
Neuropathies or neurovasculopathies that might interfere with pain evaluation
